OptumRx has partnered with CoverMyMeds to receive prior authorization requests, saving you time and often delivering real-time determinations.
Visit go.covermymeds.com/OptumRx to begin using this free service.
Please note: All information below is required to process this request.
Mon-Fri: 5am to 10pm Pacific / Sat: 6am to 3pm Pacific

Perjeta® Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)

Member Name:		
Insurance ID#:		
Date of Birth:		
Street Address:		
City:	State:	Zip:
Phone:		

Provider Information (required)

Provider Name:		
NPI#:	Specialty:	
Office Phone:		
Office Fax:		
Office Street Address:		
City:	State:	Zip:

Medication Information (required)

Medication Name:	Strength:	Dosage Form:
❑ Check if requesting **brand**	Directions for Use:	
❑ Check if request is for **continuation of therapy**		

Clinical Information (required)

Select the diagnosis below:

❑ Metastatic breast cancer
❑ Neoadjuvant treatment of breast cancer
❑ Other diagnosis: _____ ICD-10 Code(s): _____

Prescriber's Specialty:
Is Perjeta prescribed by or in consultation with an oncologist? ❑ **Yes** ❑ **No**

For metastatic breast cancer, also answer the following:
Does the patient have human epidermal receptor (HER) 2-positive metastatic breast cancer? ❑ **Yes** ❑ **No**
Has the patient received prior anti-HER2 therapy or chemotherapy for metastatic disease? ❑ **Yes** ❑ **No**
Was the patient previously treated with chemotherapy and Herceptin (trastuzumab) without Perjeta? ❑ **Yes** ❑ **No**
Select if Perjeta will be used in combination with the following:
❑ Herceptin (trastuzumab) ❑ A taxane (e.g., docetaxel, paclitaxel)

Reauthorization:
Does the patient show evidence of progressive disease while on Perjeta therapy? ❑ **Yes** ❑ **No**

For neoadjuvant treatment of breast cancer, also answer the following:
Select if the patient has the following diagnosis:
❑ HER2-positive early stage breast cancer
❑ HER2-positive locally advanced breast cancer
❑ HER2-positive inflammatory breast cancer
Select if Perjeta will be used in combination with the following:
❑ Herceptin (trastuzumab) ❑ Chemotherapy
Is the patient at high risk for recurrence? ❑ **Yes** ❑ **No**

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

_____

_____

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-800-711-4555.
This form may be used for non-urgent requests and faxed to 1-800-527-0531.

Office use only: Perjeta_Comm_2018May-W